{"text_format":"1","workbook":"xlsx","n_sheets":4,"sheets":["Cover page","Introduction","Data sheet","Table 1"],"not_rendered":{"charts":0,"images":2,"macros":1,"external_links":1,"defined_names":197,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"Cover page","index":0,"n_rows":15,"n_cols":1,"rows_kept":15,"cut":false,"hidden":false,"merged":[]}
[]
[]
[]
[]
[]
[]
[]
[]
["Baseline assessment: chronic obstructive "]
["pulmonary disease (acute exacerbation):"]
["antimicrobial prescribing"]
["NG114"]
[]
[]
["Published: 5 December 2018"]

{"sheet":"Introduction","index":1,"n_rows":12,"n_cols":1,"rows_kept":12,"cut":false,"hidden":false,"merged":[]}
["Baseline assessment tool for chronic obstructive pulmonary disease (acute exacerbation) (NICE antimicrobial prescribing guideline NG114)"]
[]
["This baseline assessment tool can be used to evaluate whether practice is in line with the recommendations in chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing.  It can also help to plan activity to meet the recommendations."]
["The tool can be used by individual services or organisations. Alternatively, an assessment completed with the involvement of all relevant services or organisations would help to develop a picture of activity in the local area."]
["It should be used in conjunction with chronic obstructive pulmonary disease (acute exacerbation) (NICE antimicrobial prescribing guideline NG114)."]
["In the first instance, consider whether the guideline is relevant and record the conclusion in the box below."]
["Is the guideline relevant?"]
[]
["The data sheet contains the recommendations from the guideline. Information can be entered about current activity relevant to the recommendation, actions needed to meet the recommendation, deadlines and the names of the responsible leads.  Useful documents can be added as hyperlinks."]
["The table can be adapted to include any other local information that is thought to be useful."]
["If it would be helpful to group the recommendations, for example those that are key priorities for implementation or by deadline, use the filter function in the data menu. "]
["National Institute for Health and Care Excellence\nLevel 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT; www.nice.org.uk\n\nCopyright\n© NICE 2024. All rights reserved. Subject to Notice of rights.\n"]

{"sheet":"Data sheet","index":2,"n_rows":23,"n_cols":10,"rows_kept":23,"cut":false,"hidden":false,"merged":[[0,0,0,9]]}
["Baseline assessment tool for chronic obstructive pulmonary disease (acute exacerbation) (NICE antimicrobial prescribing guideline NG114)"]
[]
[null,null,null,"Number of relevant recommendations",{"$f":"COUNTIF(C8:C23,\"Yes\")","v":0}]
[null,null,null,"Number of recommendations met",{"$f":"COUNTIF(E8:E23,\"Yes\")","v":0}]
[null,null,null,"Percentage of recommendations met",{"$f":"IF(ISERROR(E4/E3),\"\",E4/E3)","v":""}]
[]
["NICE recommendation","Guideline reference","Is the recommendation relevant?","Current activity/evidence","Recommendation met?","Actions needed to implement recommendation","Is there a risk associated with not implementing this recommendation?","Is there a cost or saving?","Deadline","Lead"]
["1.1  Managing an acute exacerbation of COPD with antibiotics"]
["Be aware that:\n•\tan acute exacerbation of chronic obstructive pulmonary disease (COPD) is a sustained worsening of symptoms from a person’s stable state\n•\ta range of factors (including viral infections and smoking) can trigger an exacerbation\n•\tmany exacerbations (including some severe exacerbations) are not caused by bacterial infections so will not respond to antibiotics\n•\tsome people at risk of exacerbations may have antibiotics to keep at home as part of their exacerbation action plan (see the recommendations on choice of antibiotic).\nSee the NICE guideline on COPD in over 16s.","1.1.1"]
["Treatment"]
["Consider an antibiotic (see the recommendations on choice of antibiotic) for people with an acute exacerbation of COPD, but only after taking into account:\n• the severity of symptoms, particularly sputum colour changes and increases in volume or thickness beyond the person’s normal day-to-day variation\n• whether they may need to go into hospital for treatment (see the NICE guideline on COPD in over 16s) \n• previous exacerbation and hospital admission history, and the risk of developing complications\n• previous sputum culture and susceptibility results\n• the risk of antimicrobial resistance with repeated courses of antibiotics.","1.1.2"]
["If a sputum sample has been sent for culture and susceptibility testing (in line with the NICE guideline on COPD in over 16s) and an antibiotic has been given:\n• review the choice of antibiotic when results are available, and\n• only change the antibiotic according to susceptibility results if bacteria are resistant and symptoms are not already improving (using a narrow spectrum antibiotic wherever possible). ","1.1.3"]
["If an antibiotic is given, give advice:\n• about possible adverse effects of the antibiotic, particularly diarrhoea \n• that symptoms may not be fully resolved when the antibiotic course has been completed \n• about seeking medical help if:\n- symptoms worsen rapidly or significantly, or\n- symptoms do not start to improve within 2 to 3 days (or other agreed time), or\n- the person becomes systemically very unwell.","1.1.4"]
["If no antibiotic is given, give advice about:\n• an antibiotic not being needed currently\n• seeking medical help without delay if:\n- symptoms (such as sputum colour changes and increases in volume or thickness) worsen rapidly or significantly, or\n- symptoms do not start to improve within an agreed time, or\n- the person becomes systemically very unwell.","1.1.5"]
["Reassessment"]
["Reassess people with an acute exacerbation of COPD if their symptoms worsen rapidly or significantly at any time, taking account of:\n• other possible diagnoses, such as pneumonia\n• any symptoms or signs suggesting a more serious illness or condition, such as cardiorespiratory failure or sepsis\n• previous antibiotic use which may have led to resistant bacteria.\nSend a sputum sample for culture and susceptibility testing if symptoms have not improved following antibiotic treatment and this has not been done already.","1.1.6"]
["Referral and seeking specialist advice"]
["Refer people with an acute exacerbation of COPD to hospital if they have any symptoms or signs suggesting a more serious illness or condition (for example cardiorespiratory failure or sepsis) and in line with the NICE guideline on COPD in over 16s . ","1.1.7"]
["Seek specialist advice for people with an acute exacerbation of COPD if they:\n• have symptoms that are not improving with repeated courses of antibiotics, or\n• have bacteria that are resistant to oral antibiotics, or\n• cannot take oral medicines (to explore locally available options for giving intravenous antibiotics at home or in the community, rather than in hospital where appropriate).","1.1.8"]
["1.2  Choice of antibiotic "]
["When prescribing an antibiotic for an acute exacerbation of COPD, follow table 1 for adults aged 18 years and over.","1.2.1"]
["Give oral antibiotics first line if the person can take oral medicines, and the severity of their exacerbation does not require intravenous antibiotics.","1.2.2"]
["Review intravenous antibiotics by 48 hours and consider stepping down to oral antibiotics where possible.","1.2.3"]

{"sheet":"Table 1","index":3,"n_rows":17,"n_cols":2,"rows_kept":17,"cut":false,"hidden":false,"merged":[]}
["Table 1 Antibiotic treatment for adults aged 18 years and over"]
["Treatment","Antibiotic, dosage and course length"]
["First-choice oral antibiotics (empirical treatment or guided by most recent sputum culture and susceptibilities)","Amoxicillin:\n500 mg three times a day for 5 days (see the BNF for amoxicillin dosage in severe infections)\nDoxycycline:\n200 mg on first day, then 100 mg once a day for 5 day course in total (see the BNF for doxycycline dosage in severe infections)\nClarithromycin:\n500 mg twice a day for 5 days"]
["Second-choice oral antibiotics (no improvement in symptoms on first choice taken for at least 2 to 3 days; guided by susceptibilities when available)","Use alternative first choice (from a different class)"]
["Alternative choice oral antibiotics (if person at higher risk of treatment failure; guided by susceptibilities when available)","Co-amoxiclav:\n500/125 mg three times a day for 5 days\nCo-trimoxazole:\n960 mg twice a day for 5 days\nLevofloxacin (only if co-amoxiclav is unsuitable; with specialist advice):\n500 mg once a day for 5 days\nIn December 2018, this was an off-label use of levofloxacin. See NICE's information on prescribing medicines.\nSee the MHRA January 2024 advice on restrictions and precautions for using fluoroquinolone antibiotics because of the risk of disabling and potentially long-lasting or irreversible side effects. Fluoroquinolones must now only be prescribed when other commonly recommended antibiotics are inappropriate."]
["First-choice intravenous antibiotics (if unable to take oral antibiotics or severely unwell; guided by susceptibilities when available)","Amoxicillin:\n500 mg three times a day (see the BNF for amoxicillin dosage in severe infections)\nCo-amoxiclav:\n1.2 g three times a day\nClarithromycin:\n500 mg twice a day\nCo-trimoxazole:\n960 mg twice a day (see the BNF for co-trimoxazole dosage in severe infections)\nPiperacillin with tazobactam:\n4.5 g three times a day (see the BNF for piperacillin with tazobactam dosage in severe infections)"]
["Second-choice intravenous antibiotics","Consult a local microbiologist; guided by susceptibilities"]
["See the BNF for appropriate use and dosing in specific populations, for example, in hepatic "]
["impairment, renal impairment, and when administering intravenous antibiotics."]
["If a person is having antibiotic prophylaxis, treatment should be with an antibiotic from a different class."]
["Review intravenous antibiotics by 48 hours and consider stepping down to oral antibiotics where possible."]
["People who may be at a higher risk of treatment failure include people who have had repeated courses"]
["of antibiotics, a previous or current sputum culture with resistant bacteria, or people at higher risk of "]
["developing complications."]
["Co‑trimoxazole should only be considered for use in acute exacerbations of COPD when there is "]
["bacteriological evidence of sensitivity and good reason to prefer this combination to a single antibiotic"]
["(BNF, co-trimoxazole, October 2018). "]